{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:40:06Z","timestamp":1747370406267,"version":"3.40.5"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.genhosppsych.2025.01.010","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:44:57Z","timestamp":1737247497000},"page":"80-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Letter to the editor concerning: Risk of agranulocytosis and neutropenia in patients with Parkinson's disease psychosis receiving clozapine treatment: A systematic review and meta-analysis. Limveeraprajak N, Makkapavee W, Likhitsathian S, Srisurapanont M. Possibly a greater risk?"],"prefix":"10.1016","volume":"93","author":[{"given":"Joseph H.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.genhosppsych.2025.01.010_bb0005","first-page":"95","article-title":"Clozapine use in a movement disorders clinic","volume":"45","author":"Friedman","year":"2022","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.01.010_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WNF.0000000000000491","article-title":"Absolute agranulocytosis after 9 weeks of clozapine 25 mg daily","volume":"45","author":"Friedman","year":"2022","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.genhosppsych.2025.01.010_bb0015","article-title":"Risk of agranulocytosis and neutropenia in patients with Parkinson\u2019s disease psychosis receiving clozapine treatment: a systematic review and meta-analysis","author":"Limveeraprajak","year":"2024","journal-title":"Gen Hosp Psychiatry"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.01.010_bb0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.genhosppsych.2025.01.010_bb0025","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/ph15070817","article-title":"Adverse drug reactions in relation to clozapine plasma levels: a systematic review","volume":"15","author":"Skokou","year":"2022","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834325000106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834325000106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:07:05Z","timestamp":1747368425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834325000106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":5,"alternative-id":["S0163834325000106"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2025.01.010","relation":{},"ISSN":["0163-8343"],"issn-type":[{"type":"print","value":"0163-8343"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter to the editor concerning: Risk of agranulocytosis and neutropenia in patients with Parkinson's disease psychosis receiving clozapine treatment: A systematic review and meta-analysis. Limveeraprajak N, Makkapavee W, Likhitsathian S, Srisurapanont M. Possibly a greater risk?","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2025.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}